

Detailed analysis of accumulated losses

This form has been prepared in accordance with the disclosure requirements included in the SCA Board of Directors' Decision No. (32/R.M.) of 2019 concerning procedures for companies whose shares are listed on the market, and whose accumulated losses amount to (20%) or more of their paid-up capital. Listed Companies are required to comply with the provisions of the decision as soon as their accumulated losses reach (20%) or more of their paid-up capital.

Date:	10 August 2023
Name of the Listed Company:	Gulf Pharmaceutical Industries PSC
Define the period of the financial statements:	Q2 2023
Value of the Accumulated losses:	AED 295.4 million as of 30 June 2023
Accumulated losses to paid-up capital ratio (%):	25.6% as of 30 June 2023
The main reasons for accumulated losses and the period in which these losses began.	The accumulated losses are from the prior years and the net loss for the period Q2 2023 contributed to the increase in accumulated losses.
Summary of the steps and initiatives undertaken by the company to address the accumulated losses:	<p>The following measures were taken:</p> <ul style="list-style-type: none"> ● Regain market share of core products; ● Restructure products portfolio and launch new products in the therapeutic areas in various markets; and ● Implement further process improvements and productivity enhancement initiative.
The date on which the company's general assembly approved the plan for dealing with accumulated losses:	Not applicable as the losses do not exceed 50% of the paid-up capital.

The Name of the Authorized Signatory	Sheikh Saqr Humaid AlQasimi
Designation	Chairman
Signature and Date	10 August 2023 
Company's Seal	